The characterization of phospho-Rab antibodies, including those targeting Rab10, has been conducted elsewhere.6 LRRK2, a protein kinase associated with Parkinson’s disease,7,8 has been shown to have increased kinase activity when subject to pathogenic mutations.9 Elevated levels of phospho-Rab10 have been identified in neutrophils from Parkinson’s disease patients with LRRK2 mutations.10 While inhibiting Rab10 is being explored as a potential therapeutic strategy, a deeper understanding of its mechanism is needed. Here, WEE1 is linked to Parkinson disease.